ArticleInflammopharmacology2026
Amelioration of experimentally induced-arthritis by guaiazulene through targeting inflammatory and oxidative stress biomarkers in Wistar rat.
Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA), a systemic autoimmune disease, is related with the symmetrical synovitis of the joints which causes joint pain. The intake of anti-rheumatic drugs can lead to several adverse effects. Phytochemicals are effective in treating arthritis, diabetes, cancer, autoimmune, and infectious diseases. Guaiazulene (GA) is found in various plants such as Matricaria chamomilla L., and its anti-arthritic potential is still not validated. The purpose of this research was to evaluate anti-arthritic effect of GA in Wistar rats. For anti-arthritic study on day 1, 0.15 ml Complete Freund's Adjuvant was injected in the tail vein of each rat and same concentration injected on footpad of left hind paw on 3rd day except normal control. Treatment was started orally from day 8-28th (21 days) as normal and disease controls served with vehicle, standard group with methotrexate other 3 groups served with GA at doses of 20,40, and 60 mg/kg correspondingly whereas 7th group served with combination of GA (60 mg/kg) and MTX. Treatment with GA monotherapy and in combination markedly reduced the swelling, pain and clinical arthritic scoring and reinstated weight of body biochemical and hematological parameters in treated rats as equated to disease control. The GA in combination significantly moderated the oxidation status in liver and sciatic nerve homogenates of treated animals. Treatment with GA mainly in combination notably reinstated TNF-α, IL-6, NF-ĸβ, COX-2 and IL-4 expression as quantified by qRT-PCR in contrast to disease group. It can be concluded from data that the combination of GA with MTX showed noticeable anti-arthritic potential and can be used for treating after conducting safety and clinical studies.
Indexed as
Identifiers
42033563What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.